I-Team: FDA Wants to Put Strictest Warning on Essure Birth Control - NBC New York
I-Team InvestigationsI-Team
MORE INVESTIGATIONS, MORE ANSWERS

SEND TIPS866-news244

I-Team: FDA Wants to Put Strictest Warning on Essure Birth Control

    processing...

    NEWSLETTERS

    After thousands of women complained of pain, allergic reactions, and even punctured tissue, the federal government wants to force makers of the Essure contraceptive device to print a "black box" warning on the product's packaging. Chris Glorioso reports. (Published Monday, Feb. 29, 2016)

    After thousands of women complained of pain, allergic reactions and even punctured tissue while using a contraceptive device brand Essure, the federal government wants to force its manufacturers to print a so-called black box warning on the product's packaging.

    Black box warnings are the strictest labeling requirements the FDA imposes, generally notifying doctors and patients about significant risks or life-threatening adverse events.

    Health regulators will also require Bayer, the maker of Essure, to conduct new safety research.

    The regulatory orders come more than two years after the I-Team first revealed inconsistencies in the safety studies that led the original FDA approval of Essure

    I-Team Update: New Warnings About Controversial Birth Control Device

    [NY] I-Team Update: New Warnings About Controversial Birth Control Device
    After years of reporting on Essure, a congressman now says the FDA underestimated the number of deaths associated with the birth control device called Essure. Chris Glorioso reports.
    (Published Wednesday, Feb. 17, 2016)

    "The actions we are taking today will encourage important conversations between women and their doctors," said Dr. William Maisel, chief scientist at the FDA Center for Devices and Radiological Health. "They also reflect our recognition that more rigorous research is needed to better understand if certain women are at heightened risk of complications."

    Representatives of Bayer were not immediately available for comment, though in the past the company has said it stands behind the clinical trial research that supported the safety of the contraceptive.

    Beginning in 2013, the I-Team began revealing clinical trial participants who say they reported severe and sometimes debilitating pain after being implanted with Essure. Despite the reports of pain and discomfort, researches marked their comfort level as "excellent" or "very good."

    Although the FDA wants more research, the agency stopped short of criticizing the original clinical trials.

    As part of its review, the agency conducted a “re-analysis” of clinical trial responses.

    “In the end our analysis did not find evidence of systematic or intentional modifications of study subject responses. The agency believes the original clinical data relied upon represents valid scientific evidence,” Maisel said.

    More Women Say Birth Control Records Are Altered or Missing

    [NY] More Women Say Birth Control Records Are Altered or Missing
    The Food and Drug Administration is investigating allegations from several women who say their reports of severe pain were buried by researchers studying a controversial birth control device called Essure. More than a decade after the government approved the use of Essure to block conception, thousands of women have registered complaints about discomfort and internal injuries they say are related to the device. Chris Glorioso reports.
    (Published Thursday, Oct. 1, 2015)

    The agency did not explain how a clinical trial participant could be marked down as having “excellent” comfort while at the same time reporting severe and continuing pain after implanatation.

    Shortly after the FDA announced its orders for new research and warnings, a social media group called “Essure Problems” erupted with discontent.

    An administrator of the group wrote “we are outraged that it appears as if the FDA is going to leave Essure on the market.”

    A member of the group wrote, “Epic fail again, FDA.”

    Congressman Mike Fitzpatrick (R-PA), who has sponsored a bill to circumvent FDA governance and pull Essure off the market, issued a statement saying “it’s unbelievable that it took the FDA since September to make just two recommendations with no enforcement measures and ask the manufacturer to perform another study while leaving Essure on the market.”

    Before the FDA orders for new research and a black box warning go into effect, there will be a 60-day public comment period.

    Get the latest from NBC 4 New York anywhere, anytime